Abstract: The present invention provides a piperidine derivative of formula (I) ##STR1## in which R represents a straight- or branched-chain (C.sub.1 -C.sub.19)alkyl group, a straight- or branched-chain (C.sub.2 -C.sub.19)alkenyl group, a (C.sub.3 -C.sub.6)cycloalkyl group, a cycloalkylmethyl group in which the cycloalkyl moiety has from three to six carbon atoms, a phenyl group which is optionally substituted by a halogen atom or a phenyl methyl group which is optionally substituted by a halogen atom, or an addition salt thereof, in the form of an optically pure enantiomer or of a mixture of enantiomers, a process for making them and their therapeutic application.

Abstract: A compound of formula (I) ##STR1## wherein X is hydrogen, halogen, C.sub.1 -C.sub.3 alkyl, trifluoromethyl, or C.sub.1 -C.sub.3 alkoxy;Y is hydrogen, halogen, C.sub.1 -C.sub.3 alkyl, or C.sub.1 -C.sub.3 alkoxy;R is hydroxyl, methoxy, or amine; or a pharmaceutically acceptable acid addition salt thereof, useful for treating various neurological conditions.

Abstract: The present invention provides a compound of formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, R.sub.2 represents a hydrogen atom or a straight or branched (C.sub.1 -C.sub.4)alkyl group, R.sub.3 represents a straight or branched (C.sub.1 -C.sub.7)alkyl group, a group --(CH.sub.2).sub.n OCH.sub.3 (where n is 1, 2 or 3) or a group --CH.sub.2 O(C.sub.2 H.sub.4 O).sub.m CH.sub.3 (where m is 1, 2 or 3), R.sub.4 represents a hydrogen atom or a halogen atom, R.sub.5 represents a straight or branched (C.sub.1 -C.sub.4)alkyl group and A represents phenyl or heterocyclic group optionally substituted with one or more substituents independently chosen from halogen atoms and straight or branched (C.sub.1 -C.sub.4)alkyl, straight or branched (C.sub.1 -C.sub.4)alkoxy and trifluoromethyl groups, or a cyclo(C.sub.5 -C.sub.

Abstract: Pharmaceutical compositions which comprises a core comprising alfuzosin hydrochloride which core is coated with a coating whose dissolution is pH-dependent and applications to the preparation of sustained-release dosage compositions which are unable for a once-daily oral administration.

Abstract: A compound of formula (I): ##STR1## in which R.sub.1 represents a hydrogen atom or a straight or branched (C.sub.1 -C.sub.4)alkyl group; andA represents a 5,6-dihydro-4H-imidazo[4,5,1-ij]quinol-2-yl group, a 4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-phenylmethyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 5-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 5,6-dihydro-4H-imidazo[1,5,4-de]quinoxalin-2-yl group, a 6-oxo-5,6-dihydro-4H-imidazo[4,5,1-ij]quinol-2-yl group, or a 5-methyl-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2-yl group which may be unsubstituted or substituted in the 6-position by a phenylmethyl group;or an addition salt thereof with a pharmaceutically acceptable acid.

Abstract: Compounds of formula (I) ##STR1## wherein R.sub.1 represents either a hydrogen atom, or a (C.sub.1 -C.sub.4)alkyl group,X represents either a sulphur atom, an oxygen atom or a methylene group,Z.sub.1 represents either a hydrogen atom, or a 1,1-dimethylethyl group,Z.sub.2 represents either a hydrogen atom, a triphenylmethyl group, or a phenylmethoxycarbonyl group, andn=1 or 2,and addition salts to inorganic or organic acids thereof as synthetic intermediates.

Abstract: A method for inducing thrombolysis, which method comprises administering to a patient a thrombolytically effective amount of a thrombin inhibitor which acts at the active site of thrombin, in the absence of exogenous plasminogen activator. The inhibitor is preferably argatroban, D-Phe-Pro-Arg-chloromethyl ketone, or Ac-(D-Phe)-Pro-boro-Arg-OH.

Abstract: Compounds of the formula: ##STR1## in which R represents a chlorine atom or a hydroxyl group and R.sub.4 represents a (C.sub.1 -C.sub.4)alkyl group in the R or S form are useful as synthetic intermediates.

Abstract: Compounds of the general formula (I) ##STR1## wherein R.sub.1 represents a hydrogen, fluorine or chlorine atom or a methyl, C.sub.1 -C.sub.3 alkoxy or nitro group; R.sub.3 represents a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group; R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group; or alternatively R.sub.3 and R.sub.4 complete, with the nitrogen atom to which they are attached, a 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 4,5,6,7-tetrahydrothieno[3,2-c]pyrid-6-yl or 2,3-dihydro-1H-isoindol-2-yl group; are useful for the treatment and prevention of cerebral disorders.

Abstract: Compounds of the formula: ##STR1## in which R.sub.1 represents a hydrogen or halogen atom or a methyl or C.sub.1 -C.sub.4 alkoxy group, R'.sub.1 represents a hydrogen or halogen atom, R".sub.1 represents a hydrogen atom or a methoxy group, R.sub.3 represents a C.sub.1 -C.sub.3 alkyl group, R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, or R.sub.3 and R.sub.4 together form, with the adjacent nitrogen atom, a 1,2,3,4-tetrahydroisoquinol-2-yl, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 2,3-dihydro-1H-isoindol-2-yl or 2,3,4,5-tetra-hydro-1H-3-benzazepin-3-yl, group are useful in the treatment of cerebral disorders.

Abstract: Use of eliprodil and its enantiomers for the preparation of medicines useful for the treatment of peripheral nouropathies and chronic neurodegenerative diseases of the central nervous system.

Abstract: Alfuzosin hydrochloride is stabilized as alfuzosin hydrochloride dihydrate, which is useful for the production of antihypertensive agents or dysuria curing agents.

Abstract: A compound of formula (I) ##STR1## in which R.sub.3 and R.sub.4 together represent the residue of a dihydroxy compound, andR.sub.5 represents a hydrogen atom or a (C.sub.1 -C.sub.4) alkyl group, or a salt thereof, and its use as a synthetic intermediate.

Abstract: Ifenprodil and its enantiomers are disclosed for the preparation of medicines useful for the treatment of peripheral neuropathies and chronic neurodegenerative diseases of the central nervous system.

Abstract: Compounds of formula: ##STR1## in which X represents a hydrogen atom, a C.sub.1 -C.sub.3 alkoxy group or a cyclopropylmethoxy group and Y represents a hydrogen atom or a methoxy group, are useful in the therapy of conditions.

Abstract: 1,3,4-Oxadiazol-2(3H)-one derivatives, of formula ##STR1## in which R.sub.1 represents either a hydrogen atom or a linear or branched (C.sub.1-4)alkyl group which is substituted with a hydroxyl group, a phenoxy group, a (C.sub.1-4)alkoxy group, a (C.sub.1-4)alkylthio group, a mercapto group, a (C.sub.1-4)alkoxy-(C.sub.1-4)alkoxy group, a di(C.sub.1-4)alkylamino group or an N-(C.sub.1-4)alkyl-N-propynylamino group, or represents a (C.sub.3-4)alkynyl group, andR.sub.2 either represents a linear or branched (C.sub.1-8)alkyl group which is substituted with one or more halogen atoms and/or a hydroxyl group, a 1-imidazolyl group or a 3-tetrahydropyranyl group, or represents a trifluoro(C.sub.3-5)alkenyl group,in the form of pure enantiomers or mixtures of enantiomers, including racemic mixtures, as well as the addition salts thereof with pharmaceutically acceptable acids, are useful as inhibitors of monoamine oxidase B.

Abstract: A pharmaceutical preparation intended for transdermal administration contains alfusozin [(N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydr o-2-furancarboxamide] or a salt thereof and a mixture composed of water, at least one organic solvent and at least one absorption promoter.

Abstract: A prothesis intended to be introduced into a bodily canal which includes a flexible tube for preserving the normal passage cross section of the bodily canal and a holding device for immobilizing the flexible tube in position in the canal. The holding device is a tubular structure and is radially deformable so that it can pass from a first state in which its cross section is at most equal to that of the bodily canal into which it is to be introduced to a second state in which its cross section is such that the holding device bears on the wall of an orifice of the bodily canal emerging in a natural cavity. The holding device is linked at a distance to the flexible tube.

Abstract: The invention discloses compounds formula (I) ##STR1## in which n represents the number 1 or 2, X represents a hydrogen atom or indicates that the phenyl ring to which it is attached is substituted by one or two substituents independently chosen from halogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and hydroxyl, and R represents a hydrogen atom, a group of formula --CH.sub.2 --CO.sub.2 --R.sub.1 (in which R.sub.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group) or a group of formula --CH.sub.2 --CO--NR.sub.2 R.sub.3 (in which each of R.sub.2 and R.sub.3 is independently a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group), or a pharmaceutically acceptable salt thereof, processes for their preparation and their use in the treatment of disorders of GABAergic transmission.

Abstract: Compounds of the formula: ##STR1## in which R.sub.1 represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, R.sub.2 represents a hydrogen atom, a (C.sub.1 -C.sub.4)alkoxycarbonyl group, a carboxyl group, a sodium carboxylate group, a group --CH.sub.2 OR.sub.4, where R.sub.4 is a hydrogen atom or R.sub.4 is a (C.sub.1 -C.sub.4) alkyl or (C.sub.1 -C.sub.4) acyl group, a group --CONR.sub.5 R.sub.6, or a group --CN.sub.4 R.sub.5, where R.sub.5 is a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group and R.sub.6 is a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl, hydroxyl or (C.sub.1 -C.sub.4) alkoxy or (C.sub.1 -C.sub.3) alkoxyphenyl group and R.sub.3 represents a (C.sub.1 -C.sub.4)alkyl group, and their acid addition salts are useful as synthetic intermediates.